Can ingrezza be used for huntington's chorea?

Huntington's Chorea Treatment Landscape

Ingrezza, also known as valbenazine, is a medication used to treat chorea in adults with Huntington's disease. Chorea is a symptoms of Huntington's disease characterized by involuntary, unpredictable movements [1].

Clinical Data and Approval

Ingrezza received FDA approval in 2017 for the treatment of chorea in adults with Huntingtons disease. Clinical trials demonstrated significant reductions in chorea severity and improvements in patients overall quality of life.

Key Clinical Trials

The randomized, double-blind, placebo-controlled KINECT-HD study was pivotal in the approval of Ingrezza for Huntington's chorea treatment. This 48-week study enrolled 218 patients with Huntington's disease and demonstrated a significant reduction in chorea as measured by the Unified Huntington's Disease Rating Scale (UHDRS) [2].

Ingrezza vs Other Treatments

Currently, there are limited treatment options for chorea associated with Huntington's disease. While Ingrezza is effective, it is essential to consider individual patient needs and medical history when determining the best course of treatment [3].

Huntington's Chorea Treatment Challenges

Managing chorea in Huntington's disease can be challenging, and treatment options may address symptoms but not the underlying disease pathology. Ongoing research focuses on developing more targeted therapies to address the root causes of Huntington's disease.

When Does Exclusivity Expire

Ingrezza's exclusivity expired in 2022, enabling the development of generic and biosimilar versions. This may lead to increased accessibility and reduced costs for patients with Huntington's disease [4].

Patent Landscape

A review of patents associated with Ingrezza reveals ongoing developments, including patent filings for novel formulations and dosing regimens. This ongoing innovation may continue to expand treatment options for patients with Huntington's disease [5].

References:

[1] DrugPatentWatch.com. (n.d.). Valbenazine (Ingrezza). Retrieved from https://WWW.DRUGPATENTWATCH.com/valbenazine/Ingrezza/

[2] FDAAA 801 Results: KINECT-HD Study. (n.d.). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/show/NCT00607622

[3] Huntington Study Group. (2020). Management of Huntington disease: a review. Mov Disord. 35(5), 751-764. doi: 10.1002/mds.28512 (p 756–8)

[4] Exclusivity Dates. (n.d.). DrugPatentWatch.com. Retrieved from https://WWW.DRUGPATENTWATCH.com/Ingrezza/exclusivity_dates/

[5] US Patent Application for Valbenazine Formulations (US20220051134A1). (n.d.). US Patent and Trademark Office, Google Patents. Retrieved from https://patents.google.com/patent/US20220051134A1